(S)-nicotine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Nicotine CTD PMID:12504349 1,2-dichloroethane increases expression ISO RGD:734271 6480464 ethylene dichloride results in increased expression of FMO3 mRNA CTD PMID:28189721 , PMID:28960355 1-naphthyl isothiocyanate increases expression ISO RGD:734271 6480464 1-Naphthylisothiocyanate results in increased expression of FMO3 mRNA, 1-Naphthylisothiocyanate results in increased expression of FMO3 protein CTD PMID:25193093 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:734271 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 2,3,4,7,8-Pentachlorodibenzofuran decreases expression EXP 6480464 2 more ... CTD PMID:21724226 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:734270 6480464 Tetrachlorodibenzodioxin results in decreased expression of FMO3 mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:734271 6480464 Tetrachlorodibenzodioxin results in increased expression of FMO3 mRNA CTD PMID:16214954 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:734271 6480464 Tetrachlorodibenzodioxin affects the expression of FMO3 mRNA, Tetrachlorodibenzodioxin affects the expression of FMO3 protein CTD PMID:25703434 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of FMO3 mRNA CTD PMID:21215274 , PMID:21724226 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of FMO3 mRNA CTD PMID:22298810 , PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:734271 6480464 [Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of FMO3 mRNA more ... CTD PMID:16054899 more ... 2,3,7,8-Tetrachlorodibenzofuran decreases expression EXP 6480464 2 more ... CTD PMID:21724226 3,3',4,4',5-pentachlorobiphenyl increases expression ISO RGD:734271 6480464 3 more ... CTD PMID:28163111 3,3',4,4',5-pentachlorobiphenyl multiple interactions ISO RGD:734271 6480464 3 more ... CTD PMID:28163111 , PMID:28973532 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of FMO3 mRNA CTD PMID:28522335 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:734271 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA, Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA] CTD PMID:16054899 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:734270 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA CTD PMID:28628672 3-methylcholanthrene multiple interactions ISO RGD:734271 6480464 AHR protein affects the reaction [Methylcholanthrene results in increased expression of FMO3 mRNA], Methylcholanthrene promotes the reaction [TRP53 protein binds to FMO3 5' UTR] CTD PMID:20570689 3-methylcholanthrene decreases expression ISO RGD:734271 6480464 Methylcholanthrene results in decreased expression of FMO3 mRNA CTD PMID:25926378 3-methylcholanthrene increases expression EXP 6480464 Methylcholanthrene results in increased expression of FMO3 mRNA CTD PMID:23273579 3-methylcholanthrene increases expression ISO RGD:734271 6480464 Methylcholanthrene results in increased expression of FMO3 mRNA CTD PMID:20570689 , PMID:23846873 4,4'-diaminodiphenylmethane decreases expression ISO RGD:734271 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of FMO3 mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol increases expression ISO RGD:734271 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of FMO3 mRNA CTD PMID:31881267 9-cis,11-trans-octadecadienoic acid decreases expression ISO RGD:734271 6480464 cis-9, trans-11-conjugated linoleic acid results in decreased expression of FMO3 mRNA CTD PMID:17217560 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of FMO3 mRNA CTD PMID:31881176 acrylamide increases expression ISO RGD:734271 6480464 Acrylamide results in increased expression of FMO3 mRNA CTD PMID:30807115 aflatoxin B1 decreases expression ISO RGD:734270 6480464 Aflatoxin B1 results in decreased expression of FMO3 mRNA CTD PMID:22100608 , PMID:27153756 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of FMO3 mRNA CTD PMID:33354967 aflatoxin B1 decreases methylation ISO RGD:734270 6480464 Aflatoxin B1 results in decreased methylation of FMO3 gene CTD PMID:27153756 almotriptan increases oxidation ISO RGD:734270 6480464 FMO3 protein results in increased oxidation of almotriptan CTD PMID:12642466 amitriptyline increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Amitriptyline CTD PMID:27320963 amitriptylinoxide increases abundance ISO RGD:734270 6480464 FMO3 protein results in increased abundance of amitriptyline N-oxide CTD PMID:27320963 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of FMO3 mRNA CTD PMID:16483693 ANTU increases response to substance ISO RGD:734270 6480464 FMO3 protein results in increased susceptibility to alpha-naphthyl thiourea CTD PMID:12093470 benzo[a]pyrene multiple interactions ISO RGD:734271 6480464 AHR protein affects the reaction [Benzo(a)pyrene results in increased expression of FMO3 mRNA], Benzo(a)pyrene promotes the reaction [TRP53 protein binds to FMO3 5' UTR] CTD PMID:20570689 benzo[a]pyrene increases methylation ISO RGD:734271 6480464 Benzo(a)pyrene results in increased methylation of FMO3 3' UTR, Benzo(a)pyrene results in increased methylation of FMO3 exon CTD PMID:27901495 benzo[a]pyrene increases methylation ISO RGD:734270 6480464 Benzo(a)pyrene results in increased methylation of FMO3 promoter CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:734271 6480464 Benzo(a)pyrene results in increased expression of FMO3 mRNA CTD PMID:19770486 more ... benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of FMO3 mRNA CTD PMID:21839799 benzo[b]fluoranthene increases expression ISO RGD:734271 6480464 benzo(b)fluoranthene results in increased expression of FMO3 mRNA CTD PMID:26377693 Benzo[k]fluoranthene increases expression ISO RGD:734271 6480464 benzo(k)fluoranthene results in increased expression of FMO3 mRNA CTD PMID:26377693 benzydamine multiple interactions ISO RGD:734270 6480464 Benzydamine inhibits the reaction [FMO3 protein results in increased chemical synthesis of clozapine N-oxide] CTD PMID:18809730 benzydamine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Benzydamine CTD PMID:17142560 benzydamine affects metabolic processing ISO RGD:734270 6480464 FMO3 gene polymorphism affects the metabolism of Benzydamine CTD PMID:17142560 benzydamine increases oxidation ISO RGD:734270 6480464 FMO3 protein results in increased oxidation of Benzydamine CTD PMID:21435388 beta-D-glucan increases expression ISO RGD:734271 6480464 beta-Glucans results in increased expression of FMO3 mRNA CTD PMID:27910771 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:734271 6480464 [Tetrachlorodibenzodioxin co-treated with 2 more ... CTD PMID:28433925 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of FMO3 mRNA CTD PMID:25181051 , PMID:34947998 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of FMO3 mRNA CTD PMID:33296240 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of FMO3 mRNA CTD PMID:30903817 bisphenol A multiple interactions ISO RGD:734271 6480464 [bisphenol A co-treated with retinol acetate] results in decreased expression of FMO3 mRNA more ... CTD PMID:28123100 , PMID:28433925 bisphenol A multiple interactions ISO RGD:734270 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA CTD PMID:28628672 bromobenzene increases expression EXP 6480464 bromobenzene results in increased expression of FMO3 mRNA CTD PMID:32479839 buspirone increases expression EXP 6480464 Buspirone results in increased expression of FMO3 mRNA CTD PMID:24136188 C60 fullerene increases expression EXP 6480464 fullerene C60 results in increased expression of FMO3 mRNA CTD PMID:19167457 carbon nanotube decreases expression ISO RGD:734271 6480464 Nanotubes more ... CTD PMID:25554681 carbon nanotube increases expression ISO RGD:734271 6480464 Nanotubes more ... CTD PMID:25620056 chloroprene increases expression EXP 6480464 Chloroprene results in increased expression of FMO3 mRNA CTD PMID:23125180 cholic acid increases expression ISO RGD:734271 6480464 Cholic Acid results in increased expression of FMO3 mRNA CTD PMID:17521389 choline multiple interactions ISO RGD:734271 6480464 3 more ... CTD PMID:28163111 , PMID:28973532 clofibrate decreases expression ISO RGD:734271 6480464 Clofibrate results in decreased expression of FMO3 mRNA CTD PMID:30629241 clofibric acid affects expression EXP 6480464 Clofibric Acid affects the expression of FMO3 mRNA CTD PMID:17602206 clofibric acid multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FMO3 mRNA CTD PMID:17602206 clozapine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Clozapine CTD PMID:18809730 , PMID:27320963 Clozapine N-oxide increases abundance ISO RGD:734270 6480464 FMO3 protein results in increased abundance of clozapine N-oxide CTD PMID:27320963 Clozapine N-oxide multiple interactions ISO RGD:734270 6480464 Benzydamine inhibits the reaction [FMO3 protein results in increased chemical synthesis of clozapine N-oxide] CTD PMID:18809730 Clozapine N-oxide increases chemical synthesis ISO RGD:734270 6480464 FMO3 protein results in increased chemical synthesis of clozapine N-oxide CTD PMID:18809730 cobalt dichloride decreases expression EXP 6480464 cobaltous chloride results in decreased expression of FMO3 mRNA CTD PMID:24386269 crocidolite asbestos decreases expression ISO RGD:734271 6480464 Asbestos, Crocidolite results in decreased expression of FMO3 mRNA CTD PMID:29279043 cycloheximide increases expression ISO RGD:734271 6480464 Cycloheximide results in increased expression of FMO3 mRNA CTD PMID:20570689 cyclosporin A decreases expression ISO RGD:734270 6480464 Cyclosporine results in decreased expression of FMO3 mRNA CTD PMID:20106945 , PMID:27989131 cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of FMO3 mRNA CTD PMID:21865292 dexamethasone multiple interactions ISO RGD:734271 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA, Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FMO3 mRNA] CTD PMID:16054899 dexamethasone multiple interactions ISO RGD:734270 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA CTD PMID:28628672 dexamethasone increases expression ISO RGD:734271 6480464 Dexamethasone results in increased expression of FMO3 mRNA CTD PMID:22733784 dibenz[a,h]anthracene increases expression ISO RGD:734271 6480464 1 more ... CTD PMID:26377693 dichloroacetic acid decreases expression ISO RGD:734271 6480464 Dichloroacetic Acid results in decreased expression of FMO3 mRNA CTD PMID:28962523 disodium selenite decreases expression ISO RGD:734270 6480464 Sodium Selenite results in decreased expression of FMO3 mRNA CTD PMID:24383545 diuron decreases expression EXP 6480464 Diuron results in decreased expression of FMO3 mRNA CTD PMID:25152437 endosulfan decreases expression EXP 6480464 Endosulfan results in decreased expression of FMO3 mRNA CTD PMID:29391264 ethanol increases expression ISO RGD:734271 6480464 Ethanol results in increased expression of FMO3 mRNA CTD PMID:19167417 ethanol increases expression EXP 6480464 Ethanol results in increased expression of FMO3 mRNA CTD PMID:23273579 folic acid decreases expression ISO RGD:734271 6480464 Folic Acid results in decreased expression of FMO3 mRNA CTD PMID:25629700 fumonisin B1 decreases expression ISO RGD:734271 6480464 fumonisin B1 results in decreased expression of FMO3 mRNA CTD PMID:16221962 furan increases methylation EXP 6480464 furan results in increased methylation of FMO3 gene CTD PMID:22079235 genistein increases expression ISO RGD:734271 6480464 Genistein results in increased expression of FMO3 mRNA CTD PMID:32186404 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of FMO3 mRNA CTD PMID:24136188 graphene oxide decreases expression ISO RGD:734271 6480464 graphene oxide analog results in decreased expression of FMO3 mRNA, graphene oxide results in decreased expression of FMO3 mRNA CTD PMID:33227293 Heliotrine decreases expression ISO RGD:734270 6480464 heliotrine results in decreased expression of FMO3 mRNA CTD PMID:26100227 hexane decreases methylation EXP 6480464 n-hexane results in decreased methylation of FMO3 promoter CTD PMID:23740543 imipramine oxide increases abundance ISO RGD:734270 6480464 FMO3 protein results in increased abundance of imipramine N-oxide CTD PMID:27320963 indometacin multiple interactions ISO RGD:734270 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of FMO3 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of FMO3 mRNA CTD PMID:28628672 L-methionine multiple interactions ISO RGD:734271 6480464 3 more ... CTD PMID:28163111 , PMID:28973532 metacetamol decreases expression ISO RGD:734271 6480464 3-hydroxyacetanilide results in decreased expression of FMO3 mRNA CTD PMID:18544908 metformin decreases expression EXP 6480464 Metformin results in decreased expression of FMO3 mRNA CTD PMID:31324951 methamphetamine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Methamphetamine CTD PMID:27320963 methimazole affects metabolic processing ISO RGD:734270 6480464 FMO3 gene polymorphism affects the metabolism of Methimazole CTD PMID:17050781 methimazole multiple interactions EXP 6480464 Thioacetamide inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole], trimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] CTD PMID:11414682 methimazole increases oxidation EXP 6480464 FMO3 protein results in increased oxidation of Methimazole CTD PMID:11414682 methimazole increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Methimazole CTD PMID:17050781 methotrexate affects expression ISO RGD:734271 6480464 Methotrexate affects the expression of FMO3 mRNA CTD PMID:18502557 mono(2-ethylhexyl) phthalate increases expression EXP 6480464 mono-(2-ethylhexyl)phthalate results in increased expression of FMO3 mRNA CTD PMID:16809437 N,N-dimethyltryptamine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of N, N-Dimethyltryptamine CTD PMID:27320963 N-nitrosodiethylamine increases expression ISO RGD:734271 6480464 Diethylnitrosamine results in increased expression of FMO3 mRNA CTD PMID:18691550 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of FMO3 mRNA CTD PMID:17602206 N-nitrosodiethylamine multiple interactions ISO RGD:734271 6480464 IKBKB protein inhibits the reaction [Diethylnitrosamine results in increased expression of FMO3 mRNA], MAPK14 protein inhibits the reaction [Diethylnitrosamine results in increased expression of FMO3 mRNA] CTD PMID:18691550 N-phenylthiourea increases response to substance ISO RGD:734270 6480464 FMO3 protein results in increased susceptibility to Phenylthiourea CTD PMID:12093470 N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine affects metabolic processing ISO RGD:734270 6480464 FMO3 protein affects the metabolism of Ranitidine CTD PMID:15286053 naphthalene decreases expression ISO RGD:734271 6480464 naphthalene results in decreased expression of FMO3 mRNA CTD PMID:18757308 nicotine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Nicotine CTD PMID:12504349 nitrofen increases expression EXP 6480464 nitrofen results in increased expression of FMO3 mRNA CTD PMID:33484710 Olivacine affects metabolic processing ISO RGD:734270 6480464 FMO3 protein affects the metabolism of olivacine analog CTD PMID:14709624 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of FMO3 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of FMO3 mRNA CTD PMID:25729387 ozone increases expression EXP 6480464 Ozone results in increased expression of FMO3 mRNA CTD PMID:26667333 paracetamol decreases response to substance ISO RGD:734270 6480464 FMO3 protein results in decreased susceptibility to Acetaminophen CTD PMID:24973094 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of FMO3 mRNA CTD PMID:32479839 paracetamol decreases expression ISO RGD:734270 6480464 Acetaminophen results in decreased expression of FMO3 mRNA CTD PMID:29067470 paracetamol affects expression EXP 6480464 Acetaminophen affects the expression of FMO3 mRNA CTD PMID:17366322 paracetamol decreases expression ISO RGD:734271 6480464 Acetaminophen results in decreased expression of FMO3 mRNA CTD PMID:18544908 paracetamol multiple interactions ISO RGD:734271 6480464 NFE2L2 mutant form promotes the reaction [Acetaminophen results in increased expression of FMO3 mRNA], NFE2L2 mutant form promotes the reaction [Acetaminophen results in increased expression of FMO3 protein] CTD PMID:25193093 paracetamol increases expression ISO RGD:734271 6480464 Acetaminophen results in increased expression of FMO3 mRNA, Acetaminophen results in increased expression of FMO3 protein CTD PMID:24126418 more ... paraquat decreases expression EXP 6480464 Paraquat results in decreased expression of FMO3 mRNA CTD PMID:32680482 perazine increases oxidation ISO RGD:734270 6480464 FMO3 protein results in increased oxidation of Perazine CTD PMID:11026737 perfluorononanoic acid decreases expression ISO RGD:734270 6480464 perfluoro-n-nonanoic acid results in decreased expression of FMO3 mRNA CTD PMID:32588087 permethrin decreases expression ISO RGD:734271 6480464 Permethrin results in decreased expression of FMO3 mRNA CTD PMID:30629241 phenobarbital decreases expression EXP 6480464 Phenobarbital results in decreased expression of FMO3 mRNA CTD PMID:23273579 phenobarbital decreases expression ISO RGD:734271 6480464 Phenobarbital results in decreased expression of FMO3 mRNA CTD PMID:30629241 pirinixic acid multiple interactions ISO RGD:734271 6480464 [pirinixic acid co-treated with PPARA] results in decreased expression of FMO3 mRNA CTD PMID:20813756 pirinixic acid decreases expression ISO RGD:734271 6480464 pirinixic acid results in decreased expression of FMO3 mRNA CTD PMID:16221962 more ... potassium dichromate increases expression ISO RGD:734271 6480464 Potassium Dichromate results in increased expression of FMO3 mRNA CTD PMID:23608068 progesterone increases expression EXP 6480464 Progesterone results in increased expression of FMO3 mRNA CTD PMID:20726854 ranitidine affects metabolic processing ISO RGD:734270 6480464 FMO3 protein affects the metabolism of Ranitidine CTD PMID:15286053 retinyl acetate decreases expression ISO RGD:734271 6480464 retinol acetate results in decreased expression of FMO3 mRNA CTD PMID:28123100 retinyl acetate multiple interactions ISO RGD:734271 6480464 [bisphenol A co-treated with retinol acetate] results in decreased expression of FMO3 mRNA CTD PMID:28123100 S-butyl-DL-homocysteine (S,R)-sulfoximine multiple interactions ISO RGD:734270 6480464 Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea] CTD PMID:12093470 Senkirkine decreases expression ISO RGD:734270 6480464 senkirkine results in decreased expression of FMO3 mRNA CTD PMID:26100227 serpentine asbestos decreases expression ISO RGD:734271 6480464 Asbestos, Serpentine results in decreased expression of FMO3 mRNA CTD PMID:16251409 , PMID:21514415 serpentine asbestos multiple interactions ISO RGD:734271 6480464 SPP1 gene mutant form inhibits the reaction [Asbestos, Serpentine results in decreased expression of FMO3 mRNA] CTD PMID:21514415 sulindac affects metabolic processing ISO RGD:734270 6480464 FMO3 gene polymorphism affects the metabolism of Sulindac CTD PMID:17050781 sulindac increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of Sulindac CTD PMID:15623613 , PMID:17050781 sulindac multiple interactions ISO RGD:734270 6480464 FMO3 gene polymorphism results in decreased metabolism of and results in increased susceptibility to Sulindac CTD PMID:15623613 sulindac sulfide affects metabolic processing ISO RGD:734270 6480464 FMO3 gene polymorphism affects the metabolism of sulindac sulfide CTD PMID:17142560 sulindac sulfide increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of sulindac sulfide CTD PMID:17142560 , PMID:17559352 tamoxifen decreases expression ISO RGD:734271 6480464 Tamoxifen results in decreased expression of FMO3 mRNA CTD PMID:25123088 tauroursodeoxycholic acid decreases expression EXP 6480464 ursodoxicoltaurine results in decreased expression of FMO3 mRNA CTD PMID:15885361 temozolomide increases expression ISO RGD:734270 6480464 Temozolomide results in increased expression of FMO3 mRNA CTD PMID:31758290 testosterone decreases expression ISO RGD:734271 6480464 Testosterone results in decreased expression of FMO3 mRNA CTD PMID:20844152 , PMID:21669218 tetrachloromethane decreases expression ISO RGD:734271 6480464 Carbon Tetrachloride results in decreased expression of FMO3 mRNA CTD PMID:25193093 tetrachloromethane affects expression EXP 6480464 Carbon Tetrachloride affects the expression of FMO3 mRNA CTD PMID:16239168 thioacetamide multiple interactions EXP 6480464 Thioacetamide inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] CTD PMID:11414682 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of FMO3 mRNA CTD PMID:34492290 thiourea multiple interactions ISO RGD:734270 6480464 Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea] CTD PMID:12093470 thiourea increases response to substance ISO RGD:734270 6480464 FMO3 protein results in increased susceptibility to Thiourea CTD PMID:12093470 titanium dioxide decreases expression ISO RGD:734271 6480464 titanium dioxide results in decreased expression of FMO3 mRNA CTD PMID:23557971 , PMID:27760801 titanium dioxide decreases expression EXP 6480464 titanium dioxide results in decreased expression of FMO3 mRNA CTD PMID:30012374 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of FMO3 mRNA CTD PMID:25729387 trimethylamine affects metabolic processing ISO RGD:734270 6480464 FMO3 gene polymorphism affects the metabolism of trimethylamine CTD PMID:17050781 , PMID:17142560 trimethylamine increases metabolic processing ISO RGD:734270 6480464 FMO3 protein results in increased metabolism of trimethylamine CTD PMID:12214664 more ... trimethylamine multiple interactions EXP 6480464 trimethylamine inhibits the reaction [FMO3 protein results in increased oxidation of Methimazole] CTD PMID:11414682 trimethylamine increases oxidation EXP 6480464 FMO3 protein results in increased oxidation of trimethylamine CTD PMID:11414682 trimethylamine increases oxidation ISO RGD:734270 6480464 FMO3 protein results in increased oxidation of trimethylamine, FMO3 results in increased oxidation of trimethylamine CTD PMID:11414682 , PMID:16601883 trovafloxacin increases expression EXP 6480464 trovafloxacin results in increased expression of FMO3 mRNA CTD PMID:24136188 valproic acid decreases expression ISO RGD:734271 6480464 Valproic Acid results in decreased expression of FMO3 mRNA CTD PMID:17292431 valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of FMO3 mRNA CTD PMID:29427782 valproic acid decreases methylation ISO RGD:734270 6480464 Valproic Acid results in decreased methylation of FMO3 gene CTD PMID:29154799 zaragozic acid A increases expression ISO RGD:734271 6480464 squalestatin 1 results in increased expression of FMO3 mRNA CTD PMID:27225895 zaragozic acid A decreases expression EXP 6480464 squalestatin 1 results in decreased expression of FMO3 mRNA CTD PMID:27225895
